Is Nkarta, Inc. (NKTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 45.2% / 30% | 150.6% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 45.2% / 33% | 150.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 16.0% / 33% | 53.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 45.2% / 33% | 150.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 16.0% / 33% | 53.3% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -28.9% | |
| Return on Assets (ROA) | -16.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$100M |
| Free Cash Flow | -$104M |
| Total Debt | $80M |
| Debt-to-Equity | 24.5 |
| Current Ratio | 12.7 |
| Total Assets | $501M |
Price & Trading
| Last Close | $2.14 |
| 50-Day MA | $2.28 |
| 200-Day MA | $2.08 |
| Avg Volume | 759K |
| Beta | 0.6 |
|
52-Week Range
$1.42
| |
About Nkarta, Inc. (NKTX)
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Nkarta, Inc. (NKTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Nkarta, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Nkarta, Inc.'s debt ratio?
Nkarta, Inc.'s debt ratio is 45.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 16.0%.
What are Nkarta, Inc.'s key financial metrics?
Nkarta, Inc. has a market capitalization of $147M. Return on equity stands at -28.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.